Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients ≥6 Months to <18 Years of Age With Atopic Dermatitis

NCT02612454 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT02612454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02612454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients ≥6 Months to <18 Years of Age With Atopic Dermatitis
Lead sponsor
Regeneron Pharmaceuticals
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 15, 2015
Completion date
October 7, 2026
Enrollment
880 (actual)
Sites
84

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis